Suppliers / Idt Australia

Idt Australia

Australia 96 employees Updated 9 July 2026

Idt Australia is an API and finished-dose manufacturer based in Australia. It holds 5 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 March 2025 as VAI.

5
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
7
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 March 2025 VAI US FDA
  • 31 May 2019 VAI US FDA
  • 8 December 2017 OAI US FDA
  • 19 January 2015 VAI US FDA
  • 21 February 2013 VAI US FDA
  • 21 May 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Australia, Australia 3000219354

What they file, and where

Molecule Regulators Docs
Acetazolamide US FDA 1
Hemoporfin US FDA 1
Minocycline US FDA 1
Mitoxantrone US FDA 1
Thiotepa US FDA 1

Also appears on these molecule pages

Acetazolamide API Dipyridamole finished dose Minocycline API Thiotepa API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 7 1

Comparing suppliers?

Choose your molecules and target markets. Idt Australia comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates